Maintenance Notice (2:00 - 4:00 AM July 12, 2026 UTC): The website is scheduled for maintenance. The website will be available, but some functions may experience errors. We appreciate your patience and understanding.
Product Document Searching Made Easy by 2D Code! | TCI Life Science News July 2026 | [Product Highlights] Mitochondrial Membrane Potential... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
CAS RN: 29094-61-9 | Product Number: G0369
Glipizide
Purity: >98.0%(T)(HPLC)
- N-[4-(3-Cyclohexylureidosulfonyl)phenethyl]-5-methyl-2-pyrazinecarboxamide
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | G0369 |
Purity / Analysis Method
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__1H__2__7N__5O__4S = 445.54 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 29094-61-9 |
| Reaxys Registry Number | 903495 |
| PubChem Substance ID | 125307849 |
| SDBS (AIST Spectral DB) | 52971 |
| Merck Index (14) | 4442 |
| MDL Number | MFCD00072159 |
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting Point | 206 °C |
| RTECS# | YS7640000 |
| H.S.code* | 2935.90-000 |
References
- Glipizide: a review of its pharmacological properties and therapeutic use
- The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells
- Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening
- Enhancement of the dissolution rate and bioavailability of glipizide through cyclodextrin inclusion complex
- Development of a controlled release low dose class II drug-Glipizide
- The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide, or glimperide in plasma
- Simultaneous estimation of six anti-diabetic drugs-glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay
Documents
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.